BIO-CEO Wraps Up 19th Annual Investor Conference
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded […]
cancer
Cellular Biomedicine Group Joins Force With Huntsworth Health For KOL Advocacy On Clinical Research For Knee Osteoarthritis
Cellular Biomedicine Group, Inc. (CBMG) has took on Hunstworth Health to put in order a team of medical experts for a global KOL advocacy campaign […]
Aeolus Pharma’s AEOL 10150 Declared Orphan Drug for IPF and Lung-ARS
The US FDA recently announced that the experimental drug being developed by Aeolus Pharmaceuticals, Inc. AEOL 10150 has been granted the Orphan Drug status. This […]
SpectraScience: Innovations in Cancer Detection
SpectraScience has developed patented platform technology that diagnoses colorectal cancer, which has a market size of $1, 442.6 million.
DesignMedix: Overcoming Drug Resistance
DesignMedix places great emphasis on tackling problems of drug resistant diseases, such as malaria, bacteria, and cancer.
Avantis Medical Systems Enters Enormous Endoscope Market
Avantis Medical Systems is company that is tapping into large Endoscope market which has 30 million colonoscopies globally and 15 million in the US alone.
Monteris Medical Develops a Novel Treatment for Glioblastoma
Monteris Medical is a neurosurgical company with a focus on creating unique and innovative technology to treat serious brain disorders. Their flagship product, the Neuroblate Thermal Therapy System creates minimally invasive treatments for soft tissue and brain lesions
Diagnovus Focused on Delivering Personalized Diagnostic Information and Services to Physicians Treating Patients Suffering from Rare Diseases
Diagnovus is a specialized molecular diagnostic company, focused on delivering personalized diagnostic information and services to physicians treating patients suffering from rare, orphan and less frequent diseases. We are privileged for the opportunity to serve patients and the physicians treating them.
Profound Medical’s Device on Fast Track for Commercialization
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.
OneMedForum Recap: Del Mar Pharmaceuticals
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications specifically where patients have failed contemporary therapy.